Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

ASCO 2025 Late-Breaking Sessions

Home
asco conference 2025
late breaking sessions asco 2025

Late-Breaking Sessions | ASCO 2025

The ASCO 2025 Annual Meeting is set to unveil a wave of late-breaking clinical data that may redefine standards of care across the oncology spectrum. Spanning multiple cancer types, these abstracts bring forward transformative findings in immunotherapy, antibody-drug conjugates (ADCs), PROTAC degraders, tumor-treating fields, and targeted therapies. Major pharmaceutical and biotech players—AstraZeneca, Pfizer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Arvinas, Corcept, Protagonist, Ipsen, and others—are leading the charge with practice-changing studies.

Breast Cancer at the Forefront

Hormone receptor-positive (HR+), and HER2-negative breast cancer take center stage, with late-breaking results from the SERENA-6 and VERITAC-2 trials evaluating camizestrant and vepdegestrant, respectively. These novel estrogen receptor degraders offer new hope for overcoming resistance in endocrine therapies. Meanwhile, ADCs continue to gain traction, with T-DXd (trastuzumab deruxtecan) and TRODELVY (sacituzumab govitecan) showing significant promise in HER2+ and triple-negative breast cancer, respectively. The DESTINY-Breast09 and ASCENT-04/KEYNOTE-D19 studies are poised to reshape treatment algorithms in metastatic settings.

Gastrointestinal and Pancreatic Cancers

The gastric and gastroesophageal cancer space is rich with innovation. The MATTERHORN study, investigating durvalumab + FLOT, highlights the role of immunotherapy in resectable disease. Additionally, the DESTINY-Gastric04 and disitamab vedotin-based regimens offer updated HER2-targeted strategies.

For pancreatic cancer, several phase III trials—PANOVA-3, NAPOLI-3, and others demonstrate advancements in both neoadjuvant and metastatic settings. The integration of tumor-treating fields (TTFields) and liposomal irinotecan-based regimens reflects a multidisciplinary push toward improved survival.

Precision Oncology in Colorectal and Lung Cancer

Late-breaking results from the BREAKWATER and ANCHOR trials spotlight encorafenib, cetuximab, anlotinib, and aspirin in colorectal cancer. These studies explore both first-line and adjuvant therapies in genetically defined subsets, including BRAF V600E and RAS/BRAF wild-type populations.

In non-small cell lung cancer (NSCLC), pivotal updates from CheckMate 77T, CheckMate 816, and PRAGMATICA-LUNG address both perioperative and advanced disease strategies. Agents such as nivolumab, ramucirumab, and pembrolizumab are being tested alone or in combination, aiming to extend survival in surgically resectable and immunotherapy-pretreated patients.

Expanding Therapeutic Frontiers

In gynecologic cancers, the FIRST/ENGOT-OV44 and ROSELLA trials examine combinations like niraparib + dostarlimab and relacorilant + nab-paclitaxel, respectively, in ovarian cancer settings with unmet need. Meanwhile, polycythemia vera takes a rare but meaningful spotlight with positive VERIFY trial results for rusfertide, a novel hepcidin mimetic.

Further innovations are emerging in melanoma, urothelial cancer, and prostate cancer, including combination strategies featuring cobolimab + dostarlimab (NEO-MEL-T) and padeliporfin VTP photodynamic therapy (ENLIGHTED trial).

Top 25 Late-Breaking Abstracts

Company	Drug	Trial ID/ Acronym	Phase	Patient Segment	Abstract ID	Session Type	Abstract Title
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\8CAAE084.tmp$	Camizestrant in combination with palbociclib, abemaciclib or ribociclib	NCT04964934	III	HR+/HER2-advanced breast cancer with detectable ESR1m before progression	LBA4	Plenary Session	Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase III, double-blind ctDNA-guided SERENA-6 trial
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\A3E4F0E1.tmp$	Vepdegestrant	NCT05654623	III	ER+/ HER2–negative advanced breast cancer	LBA1000	Oral Abstract Session	Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, Phase III VERITAC-2 study
	Durvalumab + FLOT chemotherapy	NCT04592913	III	Resectable gastric/gastroesophageal junction cancer (GC/GEJC)	LBA5	Plenary Session	Event-free survival (EFS) in MATTERHORN: A randomized, Phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\18C38F34.tmp$	Trastuzumab deruxtecan (T-DXd)	NCT04704934	III	second-line treatment of patients with (HER2+) unresectable/metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GEJA)	LBA4002	Oral Abstract Session	Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, Phase III DESTINY-Gastric04 study
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\C72AD5C0.tmp$	Disitamab vedotin plus toripalimab and chemotherapy /trastuzumab	NCT05980481	II/III	First-line treatment of patients with HER2-expressing locally advanced or metastatic gastric cancer.	LBA4012	Rapid Oral Abstract Session	Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\38BA3718.tmp$	JEMPERLI + Cobolimab	NCT04139902	II	Resectable stage III or oligometastatic stage IV melanoma	LBA9504	Oral Abstract Session	Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis.
	Dostarlimab and niraparib	NCT03602859	III	First-line treatment of stage III or IV non-mucinous Epithelial Ovarian Cancer	LBA5506	Oral Abstract Session	FIRST/ENGOT-OV44: A phase III clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC)
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\941464E6.tmp$	Niraparib with Abiraterone Acetate plus Prednisone	NCT04497844	III	HRR gene-mutated mCSPC	LBA5006	Oral Abstract Session	Phase III AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes
	Becotatug (JMT-101) + Irinotecan	NCT06089330	II	mCRC	LBA3516	Rapid Oral Abstract Session	JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\D5F0B3D.tmp$	Benmelstobart	NCT04964479	III	Advanced NSCLC	LBA8502	Oral Abstract Session	CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)—A randomized, single-blind, multicenter phase III study
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\916935D9.tmp$	Relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy	NCT05257408	III	Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)	LBA5507	Oral Abstract Session	ROSELLA: A phase III study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\275A1C35.tmp$	Rusfertide	NCT05210790	III	Polycythemia Vera	LBA3	Plenary Session	Results from VERIFY, a Phase III, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV)
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\6E879523.tmp$	Encorafenib plus cetuximab with or without chemotherapy	NCT04607421	III	metastatic BRAF V600E-mutant colorectal cancer	LBA3500	Oral Abstract Session	First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\AE6A834B.tmp$	Chemotherapy With mFOLFIRINOX or PAXG	NCT04793932	III	Stage I-III pancreatic ductal adenocarcinoma	LBA4004	Oral Abstract Session	Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\5EDAD7C7.tmp$	TTFields, 150kHz concomitant with Gemcitabine and Nab-paclitaxel	NCT03377491	III	locally advanced pancreatic ductal adenocarcinoma (LA-PAC)	LBA4005	Oral Abstract Session	PANOVA-3: Phase III study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC)
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\F5529603.tmp$	NALIRIFOX	NCT04083235	III	metastatic pancreatic ductal adenocarcinoma	LBA4175	Poster Session	NAPOLI 3, a phase III study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\D29DF0D8.tmp$	Anlotinib	NCT04854668	III	RAS/BRAF Wild mCRC	LBA3502	Oral Abstract Session	Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomized, phase III clinical trial (ANCHOR trial)
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\E42B04A6.tmp$	Aspirin	NCT03326791	II/III	colorectal cancer liver metastases (ASAC)	LBA3511	Clinical Science Symposium	Aspirin as secondary prevention for colorectal cancer liver metastases (ASAC): A multicenter, randomized, double-blind, placebo-controlled, phase III trial
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\D3C26597.tmp$	padeliporfin VTP	NCT04620239	III	low-grade upper tract urothelial cancer	LBA4513	Rapid Oral Abstract Session	ENLIGHTED phase III study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC)
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\C13EB689.tmp$	CYRAMZA (ramucirumab) + KEYTRUDA (pembro lizumab)	NCT 05633602	III	stage IV or recurrent NSCLC	LBA8671	Rapid Oral Abstract Session	PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer
	OPDIVO (nivolumab)	NCT04025879	III	resectable stage II-III B NSCLC	LBA8010	Rapid Oral Abstract Session	Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T
	OPDIVO (nivolumab) + chemotherapy	NCT02998528	III	Neo-adjuvant resectable NSCLC	LBA8000	Oral Abstract Session	Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\E5752763.tmp$	TRODELVY + KEYTRUDA	NCT05382286	III	locally advanced inoperable or metastatic Triple-Negative Breast Cancer	LBA109	Oral Abstract Session	Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized Phase III ASCENT-04/KEYNOTE-D19 study
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\8D4B715F.tmp$	Trastuzumab deruxtecan (T-DXd) + pertuzumab (P)	NCT04784715	III	HER2-positive, first-line metastatic breast cancer	LBA1008	Oral Abstract Session	Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09
$C:\Users\Dell9\AppData\Local\Microsoft\Windows\INetCache\Content.MSO\61054697.tmp$	Fulvestrant and Ipatasertib	NCT04650581	III	advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer	LBA1005	Oral Abstract Session	A double-blind placebo controlled randomized Phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581)